Humana (HUM) is in focus after reporting second quarter results, appointing two new directors and lowering full year 2026 GAAP EPS guidance to at least US$6.52 from at least US$8.36.

The recent second quarter report and board additions have arrived during a strong run in Humana’s stock, with a 45.57% year to date share price return and a 46.45% 1 year total shareholder return, although the 3 year total shareholder return is down 19.17%.

If Humana’s latest earnings and board changes have your attention, it may be a good time to look at other health focused opportunities through our healthcare AI stocks screener 43 healthcare AI stocks

Humana’s strong share price run now sits beside lower 2026 GAAP EPS guidance and a cautious read on medical costs. Does that combination still leave enough upside in the valuation to reward new buyers?

Most Popular Narrative: 25% Overvalued

Humana last closed at $385, compared with a widely followed fair value estimate of $308.33 based on a discount rate of 7.14%. That gap sits on a detailed narrative built around Medicare Advantage economics, Stars scores and long run margin expectations.

Humana is focusing on operational efficiency by increasing the use of AI in its contact centers to enhance customer interactions and reduce costs, likely impacting net margins. The company is making substantial efforts to improve clinical excellence, including medication adherence campaigns and member engagement through in-home visits combined with virtual health, which is expected to enhance medical margins and member experience.

Want to see how this plays through to Humana’s valuation math? The narrative leans on faster earnings growth, steadier margins and a different future P/E profile. Curious which assumptions really carry the fair value story.

Result: Fair Value of $308.33 (OVERVALUED)

However, investors still need to watch for Medicare Advantage Stars outcomes and medical cost trends, as these could weaken margins and challenge the current Humana valuation story.

Another View: Humana Through the SWS DCF Lens

The analyst narrative sees Humana as 25% overvalued at $385 against a $308.33 fair value anchor. Our DCF model tells a very different story. On that framework, Humana trades at $385 compared with an estimated future cash flow value of $999.78, which screens as materially undervalued. Which lens feels more realistic given the risks around Medicare Advantage margins and Stars scores?

To see how this cash flow based view is built, and which inputs matter most, take a closer look at the SWS DCF workup for Humana Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Humana for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With the signals on Humana feeling mixed, this is a moment to move quickly, review the full picture yourself, and weigh both sides using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Humana?

If Humana has sharpened your focus on where to put fresh capital, do not stop here. Broader opportunities across different styles and risk levels could really matter now.

• Target potential value opportunities by reviewing companies that screen as high quality yet unloved through the 52 high quality undervalued stocks.
• Prioritise resilience and sleep better at night by scanning 83 resilient stocks with low risk scores that pass tougher risk filters.
• Spot underfollowed prospects before the crowd by working through a screener containing 21 high quality undiscovered gems that highlights stronger fundamentals hiding off the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.